Ropivacaine Extended-Release Microspheres (Yichang Humanwell)

注射用罗哌卡因缓释微球 (宜昌人福药业)

Report date: 2025/07/15 20:00:07

Base Information

Drug NameRopivacaine Extended-Release Microspheres (Yichang Humanwell)
Drug Alias NameRF-16001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channels blockers
TargetsSodium channels
Therapy Area/IndicationsPainPain, Postoperative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesYichang Humanwell Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHulii Pharmaceutical (Suzhou) Co LtdBaishikang (Hangzhou) Biopharmaceutical Co LtdYichang Humanwell Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsPainPain, Postoperative
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A